Recent News

• 05.26.2026 - Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
• 05.21.2026 - Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
• 05.14.2026 - Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
• 05.13.2026 - Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
• 05.12.2026 - Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

Recent Filings

• 05.22.2026 - 3 Initial statement of beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2026 - EX-99.1 EX-99.1
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2026 - 8-K Current report
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.21.2026 - 3 Initial statement of beneficial ownership of securities